Posted by: bluesyemre | May 10, 2020

Availability of #ResearchArticles for the public during #pandemic – a case study


The coronavirus 2019 (COVID-19) disease has affected millions of lives, forcing most of us to stay at home and work. However, there is an immediate need to conduct research on potential drugs against COVID-19. In this article, the extent to which major publishers have provided access for the public to read research articles relevant to potential drug candidates for the COVID-19 disease are presented.

A systematic search of five electronic databases (Elsevier’s ScienceDirect, Taylor & Francis, SpringerLink, Wiley, and New England Journal of Medicine (NEJM)) was conducted on April 12-17, 2020. The total number of research articles containing terms ‘Ribavirin’, ‘Remdesivir’, ‘Hydroxychloroquine OR Chloroquine’, ‘Favipiravir’, ‘Lopinavir OR Ritonavir’, ‘Sarilumab’, and ‘Tocilizumab’, available for the public to read for free were determined. In this study, there was a lack of full access to research articles related to potential drugs of COVID-19 in commercial academic databases, except for ‘Remdesivir’ and ‘Favipiravir’ from NEJM.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


%d bloggers like this: